Short answer
Celcuity Inc. (CELC) filed its fiscal 2024 10-K annual report with the SEC on Mar 31, 2025.
- Top risk flagged: FDA approval risk tied to VIKTORIA-1 trial topline data expected Q2 2025, crucial for gedatolisib market authorization
FY2024 key financial metrics · XBRL
- Net income
- −$112M
- −75.3% YoY
- EPS (diluted)
- −$2.83
- −5.2% YoY
- ROE
- -96.7%
- −51.0 pp YoY
- Operating cash flow
- −$83M
- −55.1% YoY
Source: XBRL data from the Celcuity Inc. (CELC) FY2024 10-K on SEC EDGAR. USD.
Celcuity Inc. FY2024 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Clinical-stage biotech developing gedatolisib, a pan-PI3K/mTOR inhibitor targeting multiple solid tumors, primarily HR+/HER2- advanced breast and metastatic prostate cancer
- New emphasis: Initiation and enrollment updates for two Phase 3 trials (VIKTORIA-1 completed PIK3CA WT enrollment in Q4 2024; VIKTORIA-2 site activation in Q3 2024, first patient expected Q2 2025)
- Strategic shift: Focus on combining gedatolisib with CDK4/6 inhibitors to overcome resistance in HR+/HER2- advanced breast cancer after CDK4/6 therapy progression
- Quantitative highlight: 492 patients treated with gedatolisib to date; Phase 1b trial showed 63% objective response rate in 103 patients with HR+/HER2- advanced breast cancer
- Noteworthy: FDA Fast Track (Jan 2022) and Breakthrough Therapy Designations (July 2022) granted for gedatolisib, accelerating regulatory path for post-CDK4/6 progression breast cancer
Management Discussion & Analysis
- Forward-looking statements mentioned with emphasis on risks and uncertainties
- Reference made to “Risk Factors” section for additional insights
Risk Factors
- FDA approval risk tied to VIKTORIA-1 trial topline data expected Q2 2025, crucial for gedatolisib market authorization
- Clinical trial site exposure: 200+ sites across North America, Europe, Latin America, Asia-Pacific for VIKTORIA-1 and VIKTORIA-2 trials
- Supply risk from dependence on intravenous administration and timely dosing start in Q2 2025 for Phase 3 trial VIKTORIA-2
- Competitive threat from alpelisib (PIQRAY), an FDA-approved oral PI3K-α inhibitor with 39% grade 3/4 hyperglycemia adverse events
- Financial risk from $100 million borrowings under Loan Agreement, $10.3 million interest expense in 2024, with loan maturity in May 2029
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.